Russell W. Jenkins

Dr. Russell W. Jenkins

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
NBNicholas Borcherding
Nicholas Borcherding
AVAjaykumar Vishwakarma
Ajaykumar Vishwakarma
AVAndrew P. Voigt
Andrew P. Voigt
ABAndrew Bellizzi
Andrew Bellizzi
JKJacob Kaplan
Jacob Kaplan
WZWeizhou Zhang
Weizhou Zhang
Clear cell renal cell carcinoma (ccRCC) is one of the most immunologically distinct tumor types due to high response rate to immunotherapies, despite low tumor mutational burden. To characterize the tumor immune microenvironment of ccRCC, we applied single-cell-RNA sequencing (SCRS) along with T-cell-receptor (TCR) sequencing to map the transcriptomic heterogeneity of 25,688 individual CD45+ lymphoid and myeloid cells in matched tumor and blood from three patients with ccRCC. We also included 11,367 immune cells from four other individuals derived from the kidney and peripheral blood to facilitate the identification and assessment of ccRCC-specific differences. There is an overall increase in CD8+ T-cell and macrophage populations in tumor-infiltrated immune cells compared to normal renal tissue. We further demonstrate the divergent cell transcriptional states for tumor-infiltrating CD8+ T cells and identify a MKI67 + proliferative subpopulation being a potential culprit for the progression of ccRCC. Using the SCRS gene expression, we found preferential prediction of clinical outcomes and pathological diseases by subcluster assignment. With further characterization and functional validation, our findings may reveal certain subpopulations of immune cells amenable to therapeutic intervention.

1 January 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RJRussell W. Jenkins
Russell W. Jenkins
DFDavid E. Fisher
David E. Fisher

23 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ICIsrael Cañadas
Israel Cañadas
RTRohit Thummalapalli
Rohit Thummalapalli
JKJong Wook Kim
Jong Wook Kim
SKShunsuke Kitajima
Shunsuke Kitajima
RJRussell W. Jenkins
Russell W. Jenkins
DBDavid A Barbie
David A Barbie

5 September 2018 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
AAAmir R. Aref
Amir R. Aref
Marco CampisiMarco Campisi
Marco Campisi
EIElena Ivanova
Elena Ivanova
APAndrew Portell
Andrew Portell
DLDalia Larios
Dalia Larios
RJRussell W. Jenkins
Russell W. Jenkins
Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for clinical use to test novel cancer therapeutics. To be effective, these platforms need to replicate the continuous interactions that exist between tumor cells and non-tumor cell elements of the tumor microenvironment through direct cell–cell or cell–matrix contact or by the secretion of signaling factors such as cytokines, chemokines and growth factors. Given the challenges of personalized or precision cancer therapy, especially with the advent of novel immunotherapies, a critical need exists for more sophisticated ex vivo diagnostic systems that recapitulate patient-specific tumor biology with the potential to predict response to immune-based therapies in real-time. Here, we present details of a method to screen for the response of patient tumors to immune checkpoint blockade therapy, first reported in Jenkins et al. Cancer Discovery, 2018, 8, 196–215, with updated evaluation of murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS), including evaluation of the requirement for 3D microfluidic culture in MDOTS, demonstration of immune-checkpoint sensitivity of PDOTS, and expanded evaluation of tumor–immune interactions using RNA-sequencing to infer changes in the tumor–immune microenvironment. We also examine some potential improvements to current systems and discuss the challenges in translating such diagnostic assays to the clinic.

12 January 2023 in Nature
Verified
Journal Article
Closed access
PDF file
YSYi Sun
Yi Sun
OROr-Yam Revach
Or-Yam Revach
SASeth Anderson
Seth Anderson
EKEmily A. Kessler
Emily A. Kessler
CWClara H. Wolfe
Clara H. Wolfe
RJRussell W. Jenkins
Russell W. Jenkins

1 March 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MWMeng-Ju Wu
Meng-Ju Wu
LSLei Shi
Lei Shi
JDJuan Dubrot
Juan Dubrot
JMJoshua Merritt
Joshua Merritt
VVVindhya Vijay
Vindhya Vijay
NBNabeel Bardeesy
Nabeel Bardeesy
Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate–dependent enzymes, altering epigenetics and metabolism. Here, by developing mIDH1-driven genetically engineered mouse models, we show that mIDH1 supports cholangiocarcinoma tumor maintenance through an immunoevasion program centered on dual (R)-2-hydroxyglutarate–mediated mechanisms: suppression of CD8+ T-cell activity and tumor cell–autonomous inactivation of TET2 DNA demethylase. Pharmacologic mIDH1 inhibition stimulates CD8+ T-cell recruitment and interferon γ (IFNγ) expression and promotes TET2-dependent induction of IFNγ response genes in tumor cells. CD8+ T-cell depletion or tumor cell–specific ablation of TET2 or IFNγ receptor 1 causes treatment resistance. Whereas immune-checkpoint activation limits mIDH1 inhibitor efficacy, CTLA4 blockade overcomes immunosuppression, providing therapeutic synergy. The findings in this mouse model of cholangiocarcinoma demonstrate that immune function and the IFNγ–TET2 axis are essential for response to mIDH1 inhibition and suggest a novel strategy for potentiating efficacy. Significance: Mutant IDH1 inhibition stimulates cytotoxic T-cell function and derepression of the DNA demethylating enzyme TET2, which is required for tumor cells to respond to IFNγ. The discovery of mechanisms of treatment efficacy and the identification of synergy by combined CTLA4 blockade provide the foundation for new therapeutic strategies. See related commentary by Zhu and Kwong, p. 604. This article is highlighted in the In This Issue feature, p. 587